Vanderbilt-ingram Cancer Center

This phase 2 trial tests whether adding the drug nemtabrutinib to a CAR T-cell therapy called brexu-cel can help people with mantle cell lymphoma that has come back or not responded to treatment. Nemtabrutinib blocks a protein that helps cancer cells grow, while brexu-cel uses a …

This early-phase trial is testing whether combining two oral drugs, eltanexor and venetoclax, is safe and effective for people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) that has returned or not responded to prior treatment. The study will enroll 60 adult…

This phase 2 trial is testing whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to switch treatments in people with metastatic triple-negative breast cancer. The study compares standard care with a strategy where ctDNA results guide an earl…

This study tests whether removing as much tumor as possible through surgery before giving a targeted radioactive drug (Lutetium Lu 177 dotatate) works better for people with slow-growing neuroendocrine tumors that have spread to the liver. Six adults with grade 1 or 2 tumors will…

This study tests whether analyzing the genes of a kidney tumor can help doctors pick the best drug combination for each patient. Participants with advanced or metastatic clear cell kidney cancer will receive either two immunotherapy drugs (nivolumab plus ipilimumab) or one immuno…

This study tests a procedure called cryodevitalization, which uses a flexible probe to freeze and kill early-stage lung cancer cells. It is done during a standard biopsy. The goal is to find the safest freezing time and see if the treatment is tolerable for 30 patients with stage…

This early-stage trial is testing whether a combination of two imaging agents can help surgeons better detect and remove head and neck cancer. One agent uses a radioactive label for pre-surgery scans, and the other uses a fluorescent dye that makes cancer cells glow during surger…

This phase II trial is testing whether the drug neratinib, given before standard treatment, can improve outcomes for people with stage I-III HER2-mutated lobular breast cancer. Neratinib blocks a protein that helps cancer cells grow. The study will enroll 30 participants and meas…

This early-stage trial tests a fluorescent dye attached to the cancer drug nivolumab. The dye is meant to make cancer cells glow during surgery, helping surgeons remove them more precisely. The study will enroll 40 people with head and neck cancer who are already scheduled for su…

This early-phase study tests a new radioactive tracer called [18F]NOTA-ABY030, which is designed to make head and neck squamous cell carcinoma show up more clearly on PET/CT scans. About 25 adults with suspicious or unclear findings on standard scans will receive the tracer and b…

This early-phase study tests a radioactive tracer called [68Ga]Ga-ABY-025 for PET scans in 30 adults with advanced HER2-positive cancers (breast, gastric, head/neck, esophageal). Participants receive the tracer and a PET/CT scan before or during standard HER2-targeted therapy. Th…

This early-stage trial tests whether a radioactive imaging agent called 111In-panitumumab can help find cancer that has spread to lymph nodes in people with head and neck cancer. The agent binds to a protein common on cancer cells and lights up on a special scan. About 30 partici…

This early-phase trial tests a fluorescent dye attached to the cancer drug panitumumab to help surgeons see head and neck cancer during surgery. 18 adults with head and neck squamous cell carcinoma will receive the dye before surgery, and a special camera will highlight cancer ti…

This study tests a high-resolution PET-CT scanner that images removed tumors right in the operating room. About 50 adults with solid cancers will get a standard PET tracer before surgery, then the removed tissue is scanned to see if all cancer was taken out. The goal is to see if…

This study collects blood, urine, sputum, and lung tissue from 4,000 adults at high risk for lung cancer. Researchers analyze these samples to find DNA changes and other markers that could signal cancer early. The goal is to better understand how lung cancer develops and to find …

This study compares two ways to take tissue samples from lung cancer patients: standard needle biopsy (EBUS-TBNA) and a newer freezing technique (cryobiopsy). The goal is to see which method provides enough tissue for genetic testing, which helps doctors choose the best treatment…

This study collects and analyzes lung tissue from 4,000 people having surgery for early-stage non-small cell lung cancer. Researchers look for unique RNA and protein patterns (fingerprints) in the samples. The goal is to link these fingerprints to how the cancer behaves, such as …

This study follows 900 children who were treated for retinoblastoma, a rare eye cancer, to track their long-term health. Researchers will collect vision tests, tissue and saliva samples, and questionnaires from patients and their siblings. The goal is to learn more about what cau…

This study follows 2,100 people of all ages who have had sarcoma, a rare cancer, to learn how the disease and its treatments affect them over time. Participants will fill out surveys, give blood, saliva, urine, stool, and tissue samples, and wear a FitBit to track activity. The g…

This study collects and stores tissue and blood samples from up to 3,000 melanoma patients to understand the biological changes that drive the disease. Researchers will analyze the samples to identify molecular markers that may help doctors choose the most effective treatments. T…

The ICARE registry is a research database for adults interested in studies on inherited cancer risk. Participants fill out a baseline questionnaire and follow-up surveys every two years. They may also be invited to join other studies. No treatment or medication is given—this is p…

This study is creating a large repository of tissue, blood, and urine samples from women with or without breast cancer. Researchers will use these samples to study DNA, RNA, and proteins, aiming to better understand the disease. Up to 4,000 participants will donate samples over t…